| Diagnostic component | Specimen / modality | Key MLII finding | Practical notes / thresholds | Evidence |
|---|---|---|---|---|
| Core biochemical screen | Plasma / serum lysosomal enzyme assay | Markedly increased circulating lysosomal hydrolase activities due to missorting/hypersecretion; reported markers include arylsulfatase A, hexosaminidase A, and β-glucuronidase | Feng 2024 notes enzyme activities **10–20× above normal** support diagnosis; urinary glycosaminoglycans may be normal, so normal urine GAGs do **not** exclude MLII | (pqac-00000000, pqac-00000001) |
| Example plasma enzyme references | Plasma enzyme panel | Arylsulfatase A and hexosaminidase A are highlighted as significantly elevated in MLII/III α/β cohorts | Reference ranges reported by Feng 2024: ASA **50–140 nmol/mg·17 h**; HexA **29.8–63.8 nmol/mg·h**; interpret against local laboratory standards | (pqac-00000000) |
| Dried blood spot (DBS) multiplex enzymology | DBS tandem MS/MS panel | MLII/III profile can show significantly elevated **acid sphingomyelinase (ASM), iduronate-2-sulfatase (IDS), and alpha-N-acetylglucosaminidase (NAGLU)**; some enzymes may appear reduced in the same panel | Hong 2023 studied **15 MLII/III patients** versus **>500 newborn DBS**; authors suggest adding an **elevated-activity cutoff** may enable MLII/III detection as a secondary newborn-screening finding | (pqac-00000018, pqac-00000020) |
| Emerging biomarker study | Plasma MS-based biomarker discovery | BioML trial seeks a new **mass-spectrometry plasma biomarker** for ML I/II/III/IV, explicitly including MLII | Secondary aims include robustness, specificity, and long-term stability over **12- and 24-month** time frames; observational study was withdrawn, so not clinical standard yet | (pqac-00000009, pqac-00000010) |
| Molecular confirmation | Germline DNA testing (single gene, panel, exome/genome) | **Biallelic pathogenic GNPTAB variants** confirm GNPTAB-related MLII / MLIII α/β | Targeted GNPTAB sequencing is confirmatory after biochemical suspicion; severe loss-of-function variants are strongly associated with MLII | (pqac-00000001, pqac-00000004) |
| Differential molecular context | Related gene testing when phenotype overlaps attenuated forms | **GNPTG** testing is relevant mainly for MLIII gamma rather than classic MLII | Helps separate MLII from related mucolipidosis subtypes in broader lysosomal/glycoproteinosis panels | (pqac-00000004) |
| Skeletal imaging | Plain radiographs / bone survey | Characteristic **dysostosis multiplex** and progressive bone disease; presenting bone abnormalities are common | Useful early when coarse facies, growth failure, joint restriction, or abnormal skull shape raise suspicion; Dogterom reports bone abnormalities among common presenting findings | (pqac-00000013, pqac-00000005) |
| Neuroimaging | Brain and cervical spine MRI | MRI abnormalities are often nonspecific; **cervical spinal stenosis 63%** in one 11-patient cohort, with mild brain atrophy and white-matter lesions reported | Ammer 2023 found profound developmental impairment but no clear progressive neurodegeneration; cervical imaging is especially relevant because stenosis may require surveillance/intervention | (pqac-00000021, pqac-00000022) |
| Neurodevelopmental assessment | Standardized developmental testing (e.g., BSID-III, VABS-II) | Severe developmental impairment is typical; mean developmental quotient at last assessment was **36.7% (SD 20.4)** in Ammer 2023 | Not diagnostic alone, but valuable for baseline characterization, prognosis, and longitudinal follow-up | (pqac-00000021) |
| Natural-history / registry-based evaluation | Blood, urine, fibroblasts, clinical records, serial exams | Longitudinal glycoproteinosis studies include MLII to define progression, genotype-phenotype relationships, and current supportive care patterns | NCT01891422 collects blood, urine, fibroblasts, neuropsychology, and skeletal imaging data; useful for research and future endpoint development rather than routine diagnosis | (pqac-00000008, pqac-00000011) |
| Diagnostic synthesis | Integrated clinicobiochemical-genetic workup | Diagnosis is strongest when **early severe phenotype + markedly elevated plasma lysosomal enzymes + biallelic GNPTAB variants** are present | MLII often presents prenatally/neonatally/infancy with coarse facial features, skeletal disease, growth failure, and developmental delay; biochemical plus genetic confirmation is recommended | (pqac-00000001, pqac-00000000, pqac-00000004) |


*Table: This table summarizes the main diagnostic modalities used for mucolipidosis type II, from plasma enzyme testing and DBS MS/MS screening to GNPTAB confirmation and imaging. It is useful as a concise, evidence-linked workflow for populating diagnostic fields in a disease knowledge base.*